Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Packaging Corporation of America (PKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Packaging Corporation of America — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Packaging Corporation of America trades at $228.5 (market cap $20.38B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Packaging Corporation of America pays a 2.62% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PKG | |
|---|---|---|
Market Cap | $39.89B | $20.38B |
Sector | Health | Technology |
52-Week High | $491.22 | $246.31 |
52-Week Low | $278.09 | $191.41 |
Enterprise Value | $38.15B | $24.21B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Packaging Corporation of America (PKG) trades at $228.77, up 1.91% with a bullish technical signal. The company reported mixed Q1 2026 earnings with $2.40 EPS beating estimates, though revenue growth faces margin pressure. Analyst consensus is mixed with 34.6% buy ratings and a $253 price target. Recent 20% dividend increase signals management confidence amid elevated input costs.
PKG offers steady dividend income with potential upside to analyst targets, but faces headwinds from cost inflation and competitive pressures. The stock's 27.8 P/E suggests full valuation, requiring sustained earnings growth to justify current levels. Near-term performance hinges on Q2 results and operational efficiency improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
